List of Daklinza drug patents
Daklinza is owned by Bristol-Myers Squibb.
Daklinza contains Daclatasvir Dihydrochloride.
Daklinza has a total of 5 drug patents out of which 0 drug patents have expired.
Daklinza was authorised for market use on 24 July, 2015.
Daklinza is available in tablet;oral dosage forms.
Daklinza can be used as method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; method of inhibiting hepatitis c virus, method of inhibiting hepatitis c virus, method of inhibiting hepatitis c virus; method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity.
The generics of Daklinza are possible to be released after 13 June, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9421192 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
| US8642025 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
| US8329159 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Jul, 2029
(6 years from now) | |
| US8629171 | BRISTOL-MYERS SQUIBB | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
Jun, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900566 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
Market Authorisation Date: 24 July, 2015
Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; Method of inhibiting hepatitis c virus
Dosage: TABLET;ORAL
DAKLINZA family patents
18
United States
6
European Union
4
Spain
4
Japan
4
Argentina
3
Croatia
3
Korea, Republic of
3
Denmark
3
Cyprus
3
Poland
3
Hong Kong
3
Slovenia
3
China
3
Hungary
3
Taiwan
2
Colombia
2
Australia
2
EA
2
Israel
2
Canada
2
New Zealand
2
Peru
2
Chile
2
Portugal
2
Norway
2
Mexico
2
Brazil
2
South Africa
2
Lithuania
1
Luxembourg
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic